Characteristics of the study population at clinic entry
| Age | 43.8±12.8 |
| Sex: male (%) | 612 (56.1) |
| Duration of psoriasis (years) | 15.17±12.38 |
| Duration of PsA (years) | 5.65±7.95 |
| Hypertension (%) | 220 (20.2) |
| High triglycerides (%) | 197 (22) |
| High cholesterol (%) | 365 (40.6) |
| Diabetes (%) | 59 (5.5) |
| Smoking-ever (%) | 408 (44) |
| PASI | |
| <10 (%) | 619 (83.5) |
| 10–19 (%) | 77 (10.4) |
| >19 (%) | 45 (6.1) |
| Tender joint count | |
| 0 (%) | 205 (18.8) |
| 1–7 (%) | 512 (46.9) |
| >7 (%) | 374 (34.3) |
| Swollen joint count | |
| 0 (%) | 328 (30.1) |
| 1–7 (%) | 477 (43.7) |
| >7 (%) | 286 (26.2) |
| Damaged joint count | |
| 0 (%) | 704 (64.6) |
| 1–9 (%) | 280 (25.7) |
| 10–19 (%) | 60 (5.5) |
| ≥20 (%) | 45 (4.1) |
| Dactylitic digits | 0.66±1.50 |
| HAQ | |
| 0 (%) | 105 (18.9) |
| 0.1–0.5 (%) | 150 (27) |
| >0.5 (%) | 300 (54.1) |
| SF-36 PCS | |
| <30 (%) | 162 (30.5) |
| 31–45 (%) | 219 (41.2) |
| >45 (%) | 151 (28.4) |
| Current use of MTX | 168 (15.8) |
| Current use of other DMARDs | 88 (8.3) |
| Current use of anti-TNF agents | 25 (2.3) |
| Current use of corticosteroids | 30 (2.8) |
| Current use of NSAIDs | 608 (55.8) |
DMARD, disease-modifying antirheumatic drug; HAQ, health assessment questionnaire; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; TNF, tumour necrosis factor.